Annals of Reproductive Medicine and Treatment

The Usage of Metformin in Women with Polycystic Ovary Syndrome and its Effect on In vitro Fertilization

Research Article | Open Access

  • 1. Hospital Santa Rosa de Lima, Mexico
  • 2. Pediatrics Resident of Children’s Hospital of Hermosillo, Sonora
  • 3. National Institute of Medical Science and Nutrition Salvador Zubirán, Mexico
+ Show More - Show Less
Corresponding Authors
Henry Aristóteles Mateo Sánez, Hospital Santa Rosa de Lima, Mexico

Objective: To show the beneficial impact of the use of metformin in women with polycystic ovary syndrome and its success in IVF at the Fertility Clinic of Baja California.

Material and methods: A randomized controlled clinical trial in women with polycystic ovary syndrome, who were subjected to IVF treatment, in a period during January 2015 to December 2015, in the Fertility Clinic of Baja California, at Santa Rosa de Lima Hospital. Overall, there were 17 female patients between aged 26 and 40 years, from who 8 patients were administered with Dabex (metformin) 500 mg oral during the dinner; starting with 500 mg weekly, the dose was gradually increased up to1.5 gr. and Yasmin taken by oral via (3.0 mg drospirenone and 0.03 mg ethinylestradiol) 1 every 24 hours for a period of 3 weeks. The other 9 patients took oral Yasmin (drospirenone and 0.03 mg ethinylestradiol 3.00mg). SPSS 21 (Statistical Analysis Software Package) program was used for statistical analysis.

Results: There were no statistically significant differences in terms of the characteristics of the patients studied. The patients with polycystic ovary syndrome who took metformin obtained an implantation rate of 18.75% and a clinical pregnancy rate of 37.5%. Patients with polycystic ovary treated with contraceptive pills had an implantation rate of 3.4% and a clinical pregnancy rate of 22%, respectively.

Conclusion: The usage of metformin improved the success of IVF in women with polycystic ovary.


In vitro fertilization, Metformin, Polycystic ovary syndrome, Infertility, Intracytoplasmatic sperm injection


Mateo Sánez HA, Huerta Castillo PI, Ezenwa RO, Madrigal MM, Madrigal VM, et al. (2018) The Usage of Metformin in Women with Polycystic Ovary Syndrome and its Effect on In vitro Fertilization. Ann Reprod Med Treat 3(1): 1019.


S IVF: In vitro Fertilization; IVFTE: Treatment for Fertilization In vitro; ICSI: Intracytoplasmatic Sperm Injection; PAI-1: Plasminogen Activator Inhibitor 1; IGFBP-1: Insulin-like Growth Factor-Binding Protein 1


Metformin is a biguanide class drug, hypoglicemic oral drug that is the most commonly prescribed drug for diabetes type 2. In the last decade its clinical applications have increased, showing evidence mainly in metabolic syndrome patients with glucose intolerance, women seeking to get pregnant who have the polycystic ovary syndrome [1], cardiovascular disease, as well as cancer and aging. One of the mechanism of metformin is to reduce hyperinsulinemia even though the mechanism is not yet fully understood, it has been partly attributed to increased hepatic insulin sensitivity and the elevated uptake glucose in peripheral tissue [2], the ovarian diminish of excessive androgens production, the improvement in menstrual cycles and the probability of pregnancy, which is the reason that it has been mentioned the main use of metformin as a coadjutant treatment as a ovulation induction agent [3].

Some studies have evaluated the effectiveness and security of metformin as part of the treatment for IVFTE or ICSI, with the objective of accomplishment in a healthy pregnancy in women who suffer polycystic ovary syndrome [4]. For all those reasons already mentioned, it has been shown some benefits of use of metformin in patients with ovarian polycystic syndrome insulinresistant [5]. The drug already mentioned, improves glucose tolerance, increases the insulin sensitization, normalizes the relationship LH/FSH, diminish PAI -1, restores menstrual cycles, and improves rates of pregnancy.


Along the pregnancy 20% of maternal blood goes through placenta, using the cellular invasion called astrophoblast, that forms a cellular line dependent of the embryo. This cells secrete certain substances and digestive enzymes that initiate the processes of implantation [6] as the emergence of pinopods, the increment of glicodelin A, adhesion molecules, cytokines and growth factors – epidermal growth factor, colony stimulating factor 1, leukemia inhibitory factor, interleukin 1, IGFBP-1, transforming growth factor beta – and HOXA genes, associated with adequated endometrial receptivity and the success of implantation [7,8]. Some of these markers already mentioned, had been studied in women with ovarian polycystic syndrome [9].

Both insulin and insulin-like growth receptor inhibit endometrial decidualization have been studied in patients with ovarian polycystic syndrome. These patients have endometrial changes which are reflected in alterations of the appearance pattern and the concentration of the hormonal steroids receptor [10].

Polycystic ovary syndrome

The polycystic ovary syndrome is an endocrine-metabolic disorder. This disorder has heterogeneous clinical presentation, it probably has a genetic origin, which is influenced by environmental factors such as nutrition and physical activity [11]. Worldwide statistics show that the polycystic ovary syndrome affects proximally 5-10% of women, while the prevalence in Mexico is reported in 6% [12]. Being the most common endocrinopathy in reproductive age women and the most frequent cause of infertility for an ovulation and premature loss of pregnancy [13].

The first line treatment for those patients with polycystic ovary syndrome that do not desire pregnancy is combined oral contraceptives, can be used for periods longer than 6 months. The most recommended are the low dose containing ethinylestradiol 20 ug [14].

Knowing the relationship between insulin resistance and the physiopathology of the polycystic ovary syndrome, studies have emerged that refer that metformin is capable of decrease ovary hyperandrogenism, improving the metabolic, endocrine and reproductive parameters of patients. In the next study it will check the main findings of the metformin effects and the success of assisted reproduction techniques of high complexity in women with polycystic ovary syndrome.

In the following research we wanted to determine whether metformin has beneficial outcomes in the pregnancy and implantation rates in patients with polycystic ovary syndrome and promote the use of metformin as adjuvant treatment for infertility.



This randomized controlled clinical trial was performed in women with polycystic ovary syndrome, they were submitted to IVF treatment, in the period from January to December 2015. We included 17 female patients aged between 26-40 years diagnosed with polycystic ovary syndrome through medical history and pelvic ultrasound according to the Rotterdam criteria. In all the cases, the results of thyroid function tests were normal. Three patients presented amenorrhea and the rest oligomenorrhea during fertile life.

After signing an informed consent of all the patients, treatment was initiated, the first group included 8 patients treated with Dabex (metformin) 500 mg oral during the dinner; starting with 500 mg weekly; the dose was gradually increased up to 1.5 gr., and Yasmin (Drospirenone 3 mg/ ethinylestradiol 0.03 mg) 1 tablet every 24 hours for a period of 3 weeks. The other group of 9 patients were controlled with contraceptives Yasmin (Drospirenone 3 mg/ethinylestradiol 0.03 mg) oral 1 tablet every 24 hours for 3 weeks; after 10 days of stimulation with follitropin alpha 75 UI subcutaneous per day, when the follicles measure between 18 to 20 mm; is performed ovular capture, a puncture is done through the follicles with endovaginal transducer of 5 MHz brand Aloka SSD-1400. Subsequently the oocytes are aspirated using the aspiration follicular bomb brand Gen X with a medical Cook needle caliber 17G, and they are transfered to the laboratory. The oocyte maturation was observed by an optical microscope, by locating cells with polar body outside the cytoplasm of the oocyte. Already identified, they are prepared for the technique of ICSI. On the other hand for the IVF technique the oocytes were wash out along with the granulosa cells, subsequent they are moved to a second plate were the cumulus – oocyte complex is trimmed, once they were clean, they were classified morphologically and deposited in a culture medium, they were later taken to the incubator at 37 degrees Celsius and 6% of carbon dioxide. On the morrow, the confirmation of the fertilization is made by the observation of 2 pro-cell nuclei and 2 polar bodies, the cell culture is carried out until day 3 of in vitro development and the embryonic transfer is performed using a transabdominal transducer of 3.5 Mhz, brand Aloka SSD-1400. The development phase was observed with Fryedman catheter of 18 cm the 2nd day with 2-4 cells and the 3rd day with 6-8 cells. Fourteen days after the transfer, is performed the blood measurement of BhGc. Patients with BhGc positive, continue metformin dose throughout pregnancy.

The implantation rate was defined as the number of gestational sacs with active embryo among the number of embryos transfer and the clinical pregnancy rate was the number of patients with active gestation among the number of patients with embryonic transfer.

The obtained data were captured in a data base for their further analysis in the package of de Statistics analysis program SPSS21, it was used descriptive statistics for the variables, using for the quantitative variables measures of central tendency and dispersion, for the qualitative variables percentages and frequencies.


In this study, the mean age of the participants was 33.1 years old (range 26 to 41 years) and mean body mass index was 28 (range 23 to 40).

According to the statistical analysis of both groups, it was found that there were no statistically significant differences in terms of the characteristics of the studied patients such as age, count of antral follicles, oocytes aspired number, and oocytes fertilized number, endometrial thickness, and total dose of gonadotropins, culture hours and number of embryos transferred (Table 1).

In the group of patients with polycystic ovary syndrome who was administered metformin acquired an implantation rate of 18.75%, and a clinical pregnancy rate of 37.5%. The other group of patients with polycystic ovary syndrome who took contraceptives pills presented an implantation rate of 3.4% and a clinical pregnancy rate of 22%, respectively (Table 2). Additionally, this patient presented an average of endometrial thickness of 19.22% with respect of the average of 11.89% in patients who was administrated metformin, although this was not statistically significant.


In this study, throughout the pregnancy we continue to administrated metformin 1 -1.5 gr daily, however, none of the products presented anomalies or fetal risk; monitoring the first 24 hours after delivery, none of the patients presented hyper or hypoglycemia . Despite that, some authors referred that the use of metformin on pregnancy and his use as a coadjutant treatment on assisted reproduction is not yet complete standardized, it has been proved that can be classified on B category, which means that studies have been directed on animals and their toxicity or fetal risk in women has not been demonstrated [15]. Other researchers have also reported that metformin have a protective mechanism by decreasing the levels of constitutive phosphorylation of H2AX on Ser139 and constitutive activation of ATM [16].

FedorcsaÈk et al., found that treatment with metformin did not modify the amount of gonadotropins used, but did provoke an increased in the average number of recollected oocytes in the capture procedure (8.6 versus 4.6). The same study reported an increased rate of pregnancy through IVF on the patients with ovarian polycystic syndrome and normal weight [17].

Stadtmauer et al., published that the usage of metformin prior to IVF in patients with polycystic ovarysyndrome, achieved a smaller number of follicles, a lower maximum level of estradiol and a higher number of mature oocytes. This group of patients had a 70% clinical pregnancy rate, meantime in the group who didn’t used metformin this rate was a 30% [18].

Moreover, early gestational loss is one of the complications related to polycystic ovary syndrome. Some studies have evaluated the effectiveness of metformin by decreasing rates of early gestational loss compared with the clomiphene administration or fertility treatment with ovarian perforation by laparoscopy [19]

As discussed previously, polycystic ovary syndrome is frequently related with infertility. A pilot study carried out in 2001, elucidated the causes of abortions in the first trimester; there was observed an important elevation of the PAI-1 independently. In three outcomes of different pregnancies, was associated catastrophic results in each one with the presence of PAI -1. The PAI – 1 promote the abortions through thrombotic induction and placental insufficiency. As previously mentioned, the metformin foster the regulation of menstrual cycles in 91% of women with polycystic ovary syndrome that previously were infertile and with oligomenorrhea. It was shown that metformin reduced the PAI-1 activity by decreasing insulin concentration and resistance. Therefore, the administration of metformin (1.5-2.5 g/day) reduced the abortion rate from 73% to 10% and metformin was given throughout the pregnancy without producing teratogenicity [20].

In the present study we found significant differences in implantation rates, being 18.75% in women with polycystic ovary syndrome who use metformin and 3.4% in contraceptive users. The clinical pregnancy rate reached in the group of metformin users and in the group treated with contraceptives only respectively was 37.5% and 22%. The use of metformin in women with polycystic ovary syndrome improve insulin resistance by decreasing the enzyme cytochrome P450 17a activity. This leads consequently to lower levels of androgens, allowing the improvement of the intrafolicular microenvironment [21].

Earlier studies have shown that hyperinsulinemia is the primary cause of the biochemical alterations produced; metformin is the antihyperglycemic drug more used and studied in the market, its impact on the pathophysiology of the disease is overwhelming, enhanced the pathological biosynthesis of androgens and hence improve ovary function [22].

Table 1: Characteristics of the patients.

  Patient with 
metformin and 
Patient with 
  Media Media P
Age (years) 38,78 37,56 0,868
Antral follicle count 11,11 8,11 6,59
Aspired oocytes 7,00 7,22 9,74
Fertilized oocytes 5,63 5,67 0,91
11,89 19,22 0,65
Total of GnRH 1138,89 1269,44 0,595
Hours of cultivation 67,00 61,67 0,414
3,44 3,67 0,215

Table 2: Implantation rate, biochemical pregnancy and clinical pregnancy.

  Patient with 
metformin and 
Patient with 
Transference 8 9
Transferred embryos 32 58
Positive B-hCG 6 2
Women with 
gestational sac
3 2
Active embryo 6 2
Number of gestational 
sac with active 
6 2
Implantation 6/32=18.75% 2/58=3.4%
Clinical Pregnancy 3/8=37.5% 2/9=22%



Despite the size of the sample, the findings in the use of metformin as a coadjutant therapy were promising. The improvement shown in the pregnancy and implantation rate were encouraging, and without any side effects in the products of gestation. The use of metformin improves the success of pregnancy in IVF and diminish symptoms in polycystic ovary syndrome.

The knowledge in the administration of metformin in the field of reproductive medicine it is yet uncertain, opening the door for further investigations.


1. Arrigo FG Cicero, Elisa Tartagni, Sibel Ertek. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci. 2012; 8: 907-917.

2. Pryor R, Cabreiro F2. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015; 471: 307-322.

3. Palomba S, Falbo A, La Sala G. Effects of metformin in women with polycystic ovary syndrome treated with gonadotropins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013; 120: 267-276.

4. Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and duringIVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014; 11.

5. Nölting M. Galluzzo L, Pérez LB. Consenso sobre Síndrome de ovario poliquístico. FASGO. 2011; 10: 71-75

6. Prince AL, Antony KM, Ma J, Aagaard KM. The microbiome and development: a mother’s perspective. Semin Reprod Med. 2014; 32: 14-22.

7. Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol. 2003; 101: 785-793.

8. Lathi RB, Swierz L, Basina M, Giudice LC. The endometrium in polycystic ovary syndrome. CurrOpinEndocrinol Diabetes. 2002; 9: 480-485.

9. Daftary GS, Taylor HS. Molecular markers of implantation: clinical implications. Curr Opin Obstet Gynecol. 2001; 13: 269-274.

10. Coetzee EJ, Jackson WP. Pregnancy in established non-insulindependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J. 1980; 58: 795-802.

11. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006; 20: 193-205

12. Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest. 2010; 69: 274-280.

13. Fábregues, F. Epidemiología y conceptos generales. En: Checa M.A, Espinós J.J, Matorras R. Síndrome de Ovario Poliquístico. Panamericana. 2006; 13-23.

14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, EscobarMorreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. En: Fertility and Sterility. 91; 456-488

15. American College of Obstetrician s and Gynecologists (ACOG). Polycystic ovary syndrome. Washington 2009.

16. Halicka HD, Zhao H, Li J, Traganos F, Zhang S, Lee M , et al. Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY). 2011; 1028- 1038.

17.  Kjøtrød SB, von Düring V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod. 2004; 19: 1315-1322.

18. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril. 2001; 75: 505-509.?

19. Legro RS1, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007; 356: 551-66.

20. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilott study. Fértil Steril. 2001; 75: 46-52

21. Paglia T, Cianci A, De Leo V, Cianci A. Metformin treatment redues ovarian cytochrome P-450 c17 alpha response to human chorionic gonadotrophin in women. With insulin resistance-relatd polycystic ovary syndrome. Human Reprod. 2000; 15: 21-23.

22. Mateo-Sánez HA, Mateo-Sánez E, Hernández-Arroyo L, SalazarRicarte EL. La administración de metformina en el síndrome de ovario poliquístico. Rev Mex Reprod. 2012, 4: 141-146.

Received : 24 Aug 2017
Accepted : 20 Jan 2018
Published : 22 Jan 2018
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X